Gufic Biosciences LimitedQ1 FY27 Results & Financial Update
Gufic Biosciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹260.82 Cr, PAT ₹22.31 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Gufic Biosciences price & chart
Market price₹404.50
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Gufic Biosciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
During the quarter ended June 30, 2026 (Q1 FY27), Gufic Biosciences reported consolidated revenue from operations of INR 260.82 crore, alongside total income of INR 261.28 crore.
Total expenses for the quarter stood at INR 231.24 crore, reflecting cost of materials consumed at INR 106.14 crore, purchases of stock-in-trade at INR 14.03 crore, and employee benefits expenses of INR 41.80 crore.
The company posted a consolidated profit before tax (PBT) of INR 30.04 crore for the first quarter of fiscal 2027.
Tax expenses for the quarter aggregated to INR 7.73 crore, comprising INR 6.08 crore in current tax and INR 0.16 crore in deferred tax.
Consolidated net profit for the period (PAT) reached INR 22.31 crore, translating to a basic and diluted earnings per share (EPS) of INR 2.22 for the quarter.
Other comprehensive income (OCI) for Q1 FY27 was recorded at INR 0.08 crore (net of taxes), bringing total comprehensive income to INR 22.39 crore.
During the board meeting held on August 14, 2026, the directors also approved the proposed incorporation of a new subsidiary in the Philippines to expand the company's international marketing and distribution footprint.
For the first quarter of fiscal year 2027 (Q1 FY27) ended June 30, 2026, Gufic Biosciences reported consolidated revenue from operations of INR 260.82 crore.
01 · Business model
What does Gufic Biosciences do?
Gufic Biosciences Limited is an established pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse portfolio of pharmaceutical formulations, bulk drugs, and related medical products.
The company operates multiple manufacturing facilities across India, including units located in Kabilpore (Navsari, Gujarat), Pithampur (Dhar, Madhya Pradesh), and Udyambag (Belgaum, Karnataka), supporting both domestic distribution and international expansion.
Gufic manages its business operations within a single primary operating segment focused entirely on pharmaceuticals, delivering therapeutics across various medical specialties through its established distribution channels.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹260.82 Cr |
| Total income | ₹261.28 Cr |
| Profit before tax | ₹30.04 Cr |
| Profit after tax | ₹22.31 Cr |
| EPS | ₹2.22 |
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations for Q1 FY27 was reported at INR 260.82 crore, with other income contributing an additional INR 0.46 crore to bring total consolidated income to INR 261.28 crore.
The company recorded consolidated revenue from operations of INR 260.82 crore for Q1 FY27.
Other income contributed INR 0.46 crore to the total consolidated income of INR 261.28 crore during the quarter.
What drove margins
Cost of materials consumed for the quarter stood at INR 106.14 crore, while purchases of stock-in-trade accounted for INR 14.03 crore, and changes in inventories of finished goods, work-in-progress, and stock-in-trade showed a negative adjustment of INR 0.52 crore.
Employee benefits expenses were recorded at INR 41.80 crore, finance costs stood at INR 9.32 crore, depreciation and amortisation expenses amounted to INR 7.71 crore, and other expenses were reported at INR 57.41 crore.
Material consumption costs stood at INR 106.14 crore for the quarter ended June 30, 2026.
Employee costs were recorded at INR 41.80 crore for Q1 FY27.
Finance costs were reported at INR 9.32 crore, while depreciation and amortization expenses stood at INR 7.71 crore for the quarter.
Other operating and administrative expenses accounted for INR 57.41 crore in the consolidated statement.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company's business activity falls within a single primary operating segment, which is Pharmaceuticals, in accordance with Indian Accounting Standards.
Geography and market mix
The Board approved the incorporation of a subsidiary named Gufic Philippines Inc. (or similar approved name) to undertake marketing, sale, and distribution of pharmaceutical products and manage intellectual property rights in the Philippines.
05 · Strategy & new businesses
How the company is trying to change its growth mix
The company proposed to invest up to USD 250,000 (or equivalent in Philippine Peso) by way of cash subscription to equity shares, holding approximately 99.99% of the proposed subsidiary to facilitate regional market expansion.
The board approved the establishment of Gufic Philippines Inc. as a subsidiary, with Gufic proposing to hold approximately 99.99% equity through a cash subscription of up to USD 250,000 to expand international market presence.
06 · Reported developments
What changed operationally
The company maintained positive profitability with a consolidated net profit of INR 22.31 crore for Q1 FY27.
Gufic delivered a consolidated net profit of INR 22.31 crore for Q1 FY27 with basic EPS of INR 2.22.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
Subsidiary Formation Approval
The board of directors approved the incorporation of Gufic Philippines Inc. as a subsidiary with an investment of up to USD 250,000 to bolster international distribution and intellectual property management.
08 · Key Q&A
The quarter, answered directly
What does Gufic Biosciences do?
Gufic Biosciences Limited is an established pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse portfolio of pharmaceutical formulations, bulk drugs, and related medical products.
What is the clearest takeaway from Q1 FY27?
During the quarter ended June 30, 2026 (Q1 FY27), Gufic Biosciences reported consolidated revenue from operations of INR 260.82 crore, alongside total income of INR 261.28 crore.
What drove revenue or demand?
Revenue from operations for Q1 FY27 was reported at INR 260.82 crore, with other income contributing an additional INR 0.46 crore to bring total consolidated income to INR 261.28 crore.
What mattered most for margins or profitability?
Cost of materials consumed for the quarter stood at INR 106.14 crore, while purchases of stock-in-trade accounted for INR 14.03 crore, and changes in inventories of finished goods, work-in-progress, and stock-in-trade showed a negative adjustment of INR 0.52 crore.
What changed operationally beyond the headline numbers?
The company proposed to invest up to USD 250,000 (or equivalent in Philippine Peso) by way of cash subscription to equity shares, holding approximately 99.99% of the proposed subsidiary to facilitate regional market expansion.
What should the next disclosure help confirm?
Completion of incorporation formalities and regulatory registrations for the proposed Philippine subsidiary within the 12-month timeframe.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Regulatory and Statutory Approvals: Completion of incorporation formalities and regulatory registrations for the proposed Philippine subsidiary within the 12-month timeframe.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.